Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Total Liabilities (2021 - 2025)

Bioregenx's Total Liabilities history spans 5 years, with the latest figure at $4.9 million for Q4 2025.

  • Quarterly results put Total Liabilities at $4.9 million for Q4 2025, up 27.28% from a year ago — trailing twelve months through Dec 2025 was $4.9 million (up 27.28% YoY), and the annual figure for FY2025 was $4.9 million, up 27.28%.
  • Total Liabilities for Q4 2025 was $4.9 million at Bioregenx, up from $4.8 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $4.9 million in Q4 2025 to a low of $101553.0 in Q1 2022.
  • The 5-year median for Total Liabilities is $2.9 million (2023), against an average of $2.2 million.
  • The sharpest move saw Total Liabilities rose 10.9% in 2023, then surged 1480.07% in 2024.
  • Year by year, Total Liabilities stood at $211996.0 in 2021, then grew by 22.97% to $260691.0 in 2022, then skyrocketed by 1026.69% to $2.9 million in 2023, then skyrocketed by 32.36% to $3.9 million in 2024, then grew by 27.28% to $4.9 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $4.9 million, $4.8 million, and $4.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.